NEWS RELEASES

SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS
 

09.01.11

Oncology Drug Development and Personalized Medicine: Clinical Evaluation of Combinations of Novel Targeted Drugs and Co-development of Companion Diagnostics

07.07.11

Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer

04.12.11

Approval of AstraZeneca’s Multi-targeted Anticancer Drug Vandetanib for the Treatment of Advanced Medulllary Thyroid Cancer Broadens the Application of Inhibitors of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer

10.13.10

Novel Immunotherapy/Therapeutic Vaccines in Malignant Melanoma-Global Development Status

02.23.09

New Medicine's Oncology KnowledgeBASE (nm|OK)-A Comprehensive Resource in the Diagnosis/Prognosis and Drug Development in Cancer

06.11.08

Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success

03.26.08

Diagnostics, Theragnostics, Prognostics, Pharmacogenomics and Biomarkers in Oncology
Numerous Commercial and Academic Groups are Developing Products/Technologies that Will Play a Critical Role in Clinical Trial Design and Patient Selection and Treatment Assessment, and May Determine the Future Success of Anticancer Drugs

02.19.08

Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics

11.27.07

Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of nearly $5 billion in the First Nine Months of 2007

09.18.07

Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development

07.17.07

Oncology Drug Development-Mid-Year 2007 Update

05.29.07

Oncology Drug Development Update - Targeted Drugs from the 2007 Meeting of the American Association of Cancer Research (AACR)

04.03.07

Oncology Drug Development Update - EGFr-Targeted Drugs: Vectibix Setback, EGFr Testing

03.27.07

Oncology Drug Development Information Resources

01.09.07

Oncology Drug Development Information Resources

10.09.06

Oncology Drug Development Update - Targeting the Epidermal Growth Factor Receptor (EGFr) Signal Transduction Pathway

07.12.06

Oncology Drug Development Update - Over 600 Novel Anticancer Agents in Development were Added in New Medicine's Oncology KnowledgeBASE (nm|OK) in the first 6 months of 2006, Including Over 190 Agents in Clinical Development Targeting over 154 Distinct Molecular Markers

02.07.06

Oncology Drug Development Update - Monotherapy Phase I Clinical Trials of Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapeutics/Vaccines

11.30.05

Oncology Drug Development Update - Monotherapy Phase I Clinical Trials of Novel Drugs/Formulations-Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapy/Vaccines

10.10.05

Oncology Drug Development Update

07.19.05

Oncology Drug Development: the c-SRC Signaling Pathway

05.03.05

Oncology Drug Development Update - Over 545 New Drugs were Added in the First Four Months of 2005, from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK)

04.26.05

Update on Pancreatic Cancer - Epidemiology · Molecular Markers · Prognosis, Diagnosis and Disease Monitoring · State-of-the-Art Treatments · Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents, and Immunotherapy/Vaccines

04.05.05

Oncology Drug Development Update - The Records of Numerous Novel Spindle Poisons, Including Taxanes, Epothilones and Other Antimitotics, have been Updated in New Medicine's Oncology KnowledgeBASE (nm|OK)

02.16.05

Oncology Drug Development Update - Over 142 Records of Novel Drugs Were Added in January 2005 from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK)

07.08.04

Oncology Drug Development Update June 2004

09.16.03

Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials

04.30.03

Anticancer Agents From Antibiotic Sources - New Antibiotics, Analogs and Derivatives, and Targeted Cytotoxics - a Report From New Medicine

11.05.02

Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials

9.18.02

Update on Spindle Poisons-Taxanes, Vinca Alkaloids and Novel Anticancer Drugs Acting by Disrupting the Cytoskeleton of Tumor Cells

8.07.02

Oncology Drug Development Update 2002

6.26.02

Numerous Novel Anticancer Agents Are in Early-Stage of Clinical Development

6.05.02

New Strategies Regarding Combination Therapies, Target Validation and Chemoprevention Taking Center Stage in Cancer Drug Development

3.12.02

Future Oncology Issues a Comprehensive Report on Clinical and Market Developments in the Taxane Group of Spindle Poisons

11.05.01

New Medicine posted estimates of global markets for anticancer agents and adjuncts on its subscription-based oncologyknowledgebase.net website

7.10.01

Over 300 Clinical Trials Involving More Than 100 Anticancer Agents Acting By Regulatory Rather Than Cytotoxic Mechanisms Have Been Initiated According to New Medicine's Oncology KnowledgeBASE (nm/OK) Commercialization of These Agents as Monotherapies and/or Combination Therapies Will Revolutionize the Way Cancer is Treated

3.20.01

Over 547 Anticancer Drugs Based on Novel Mechanisms Are in Development With Many in Late-Stage Clinical Trials, According to Oncology KnowledgeBASE
Commercialization of These Agents Will Revolutionize the Way Cancer Is Treated

11.08.00

Over 1,500 Anticancer Agents are in Active Development, With 522 in Clinical Trials, According to Web-Based New Medicine's Oncology KnowledgeBASE (nm/OK)

9.27.00

Future Oncology Publishes A Comprehensive Review of Lung Cancer Comprising WorldWide Epidemiology, Current Treatment Approaches, Novel Agents In Development, And Market Opportunities

12.07.99

Future Oncology Publishes A Comprehensive Review Of Markets Of Oncology Drugs

8.03.99

New Medicine Issues A Comprehensive Report On Worldwide Product Development And Market Opportunities In The Management Of Moderate-To-Severe Pain With Special Emphasis On Cancer-Related Pain

6.01.99

Demo of New Medicine’s Comprehensive Oncology Knowledgebase Now On The Company’s Web Site

10.07.98

Future Oncology Publishes A Comprehensive Review Of Prostate Cancer And Identifies Over 180 Separate Products In Development To Treat This Disease

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM